We focus on the development of novel medicines using our proprietary platform which we call Extreme Genetics.
We are a biopharmaceutical company focused on the development of novel medicines through the application of our proprietary discovery platform, which we refer to as Extreme Genetics®. Our product candidates are based on genetic insights derived from our research of families where individuals exhibit severe traits, or phenotypes. We apply our expertise to predict which phenotypes are caused by single-gene defects. By identifying and characterizing the single-gene defects responsible for such severe phenotypes, we gain valuable insights into their function in human biology and their potential as drug targets. Given that these targets are often involved in diseases beyond the rare genetic disorders in which they are first identified, we are developing proprietary product candidates to treat both orphan as well as more prevalent diseases.
Sept 10, 2013 – Xenon Announces Appointment of Ian C. Mortimer as Chief Financial Officer
June 10, 2013 – Xenon Licenses Antisense Drug XEN701 from Isis and Initiates Preclinical Toxicology Studies
April 23, 2013 – Teva and Xenon Announce FDA Orphan Drug Designation for Pain Drug XEN402